Drug & Alcohol Rehabilitation Clinics in European Union 2026: Industry Statistics & Trends

The drug and alcohol rehabilitation clinics industry in the European Union comprises specialized establishments that provide residential and outpatient care, detoxification, and psychosocial therapies for individuals suffering from substance use disorders. The sector operates within a highly regulated public health and social services framework, heavily influenced by state funding and national health policies. According to the European Union Drugs Agency (EUDA) European Drug Report 2025, approximately 511,000 clients received opioid agonist treatment alone in the EU during 2023. The industry is moving toward highly individualized, evidence-based care models to manage shifting patterns of con

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Drug & Alcohol Rehabilitation Clinics in European Union industry cover?

This industry encompasses medical and residential facilities that provide structured treatment programs for alcohol dependence and illicit drug addiction. Services include medically supervised withdrawal management (detoxification), residential rehabilitation, outpatient counseling, and long-term harm reduction interventions. These activities are distinct from general hospital services, focusing instead on psychiatric, psychological, and social rehabilitation to support long-term recovery.

• •Includes both short-term inpatient detoxification units and extended-stay therapeutic communities.
• •Integrates psychosocial interventions, such as cognitive behavioral therapy, with pharmacological treatments like opioid agonist therapies.
• •Excludes purely social welfare accommodation that does not feature a structured clinical rehabilitation component.

Who operates in the industry and how is it structured?

The European market is structurally diverse, with services delivered through a mix of public health systems, non-profit non-governmental organizations (NGOs), and private commercial operators. The prevalence of each operator type varies significantly by Member State, depending on national healthcare reimbursement frameworks and historical infrastructure. Public and state-subsidized third-sector facilities dominate the volume of care, while private-pay luxury and boutique clinics target a smaller, self-funding demographic.

• •The non-profit sector represents a major operational pillar, frequently executing state-funded service contracts.
• •Cross-border care is common among high-net-worth individuals seeking private rehabilitation in Southern or Western Europe.
• •Public funding models rely heavily on national health insurance schemes or direct budget allocations from regional health authorities.

What drives demand in the industry?

Demand for rehabilitation services is driven by the overall prevalence of high-risk substance use, shifting consumption trends, and public health policy initiatives aimed at reducing drug-related mortality. The proliferation of synthetic substances and highly potent synthetic opioids creates an urgent need for specialized clinical interventions. Additionally, increased political and financial backing for harm reduction and treatment expansion directly fills operational capacity across the EU.

• •Opioid use remains a primary driver for intensive clinical treatment, accounting for 63,500 specialist drug treatment entries in the EU in 2023 (EUDA 2025).
• •The rising purity and availability of stimulants, particularly cocaine, have accelerated first-time treatment presentations across Western Europe.
• •National health surveys indicate sustained high levels of illicit substance use, with an estimated 24 million European adults having used cannabis in the past year (EUDA 2025).

Who are the notable companies in the industry?

The competitive landscape for specialized substance abuse rehabilitation in the EU is highly fragmented, with few pure-play publicly traded operators due to the heavy involvement of public health bodies and charitable foundations. Corporate operators in this space are typically large, diversified healthcare or residential care conglomerates that manage specialized psychiatric and addiction treatment clinics alongside elderly care or general medical facilities. These organizations expand their footprints through selective regional acquisitions and public-private partnerships.

• •Clariane SA (formerly Korian) operates a network of post-acute care and mental health clinics across Europe, including specialized psychiatric and addiction treatment services.
• •LNA Santé SA manages a portfolio of healthcare facilities in France and Belgium, offering specialized follow-up care and rehabilitation, which includes substance dependency management.
• •Orpea SA (operating under the global brand emeis) maintains psychiatric care facilities across multiple EU Member States that address severe dependency and comorbid disorders.
• •Sanoptis, while operating primarily as a consolidated medical network, reflects the broader trend of institutional investment into European specialized clinical infrastructure.

What are the recent trends and outlook?

The industry is experiencing an evolution in treatment protocols to address polysubstance use, where individuals combine multiple illicit substances or alcohol, compounding clinical complexity. Operators are increasingly integrating digital health solutions, such as remote aftercare applications and tele-psychiatology, to extend the continuity of care post-discharge. The long-term outlook points toward steady demand, supported by the establishment of the enhanced European Union Drugs Agency (EUDA) mandate to strengthen monitoring and response capacities.

• •Treatment centers are adapting facilities to handle an influx of synthetic cathinone and nitazene-related admissions.
• •A growing clinical focus is being placed on 'dual diagnosis' programs that treat substance addiction and co-occurring psychiatric conditions concurrently.
• •The institutional transition from the legacy EMCDDA to the EUDA reinforces unified European data collection and clinical standards.

How is the industry regulated?

Operators must comply with stringent national healthcare regulations, clinical auditing standards, and professional licensing requirements established by each EU Member State's ministry of health. Furthermore, individual facilities are bound by strict European legal frameworks concerning data protection, patient rights, and the handling of controlled pharmaceuticals used in substitution therapy. Strict oversight governs the procurement, storage, and dispensing of agonist substances like methadone and buprenorphine.

• •Facilities must strictly adhere to the General Data Protection Regulation (GDPR) regarding sensitive patient medical and psychiatric histories.
• •Substitution treatment programs are subject to rigorous national narcotics tracking regulations and frequent compliance inspections.
• •Clinical guidelines are increasingly harmonized with evidence-based recommendations disseminated by the European Union Drugs Agency.

Government, statistical and trade sources used for this Claight analysis.

• European Union Drugs Agency (EUDA) European Drug Report 2025 ·
• Eurostat NACE Rev. 2 Statistical Classification of Economic Activities